1422206-13-0

Basic information

• Product Name: methyl 1-methyl-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate
• Synonyms: methyl 1-methyl-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate
• CAS NO: 1422206-13-0
• Molecular Weight: 377.323
• Mol File: 1422206-13-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 1-methyl-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-methyl-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate(1422206-13-0)
• EPA Substance Registry System: methyl 1-methyl-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate(1422206-13-0)

Safety Data

• Hazardous Substances Data: 1422206-13-0(Hazardous Substances Data)

Upstream product

• 1422205-93-3 methyl 6-amino-1H-benzimidazole-4-carboxylate 
• 1169789-11-0 methyl 6-nitro-1H-benzimidazole-4-carboxylate 
• 37619-25-3 methyl 1H-benzo[d]imidazole-4-carboxylate 
• 1422205-94-4 methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate 
• 74-88-4 methyl iodide 

Relevant articles and documents

HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR

The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: wherein R 1 and R 2 are same or diferent aromatic ring, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevension of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.